500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA
News, Articles of Incorporation
Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Kymera Therapeutics Enters $500 Million Sales Agreement with TD Cowen
Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Announces Pricing of Upsized $602 Million Public Offering
Reg. FD
Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
Announces Third Quarter 2025 Financial Results and Provides a Business Update
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence